Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

PHASE4CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Alpha1-proteinase Inhibitor DeficiencyEmphysema
Interventions
BIOLOGICAL

Alpha1-proteinase inhibitor

60 mg/kg body weight/week intravenous

OTHER

Placebo

Lyophilized preparation: 60 mg/kg body weight/week intravenous

Trial Locations (28)

9

Study Site, Dublin

2010

Study Site, Darlinghurst

2305

Study Site, New Lambton

2900

Study Site, Hellerup

3065

Study Site, Fitzroy

4066

Study Site, Brisbane

5000

Study Site, Adelaide

6009

Study Site, Nedlands

8000

Study Site, Aarhus

12200

Study Site, Berlin

14059

Study Site, Prague

17033

Study Site, Hershey

20502

Study Site, Malmo

33136

Study Site, Miami

45239

Study Site, Essen

51014

Study Site, Tartu

69126

Study Site, Heidelberg

75708

Study Site, Tyler

80206

Study Site, Denver

90220

Study Site, Oulu

90419

Study Site, Nuremberg

V5Z4E1

Study Site, Vancouver

B3H3A7

Study Site, Halifax

M5T2S8

Study Site, Toronto

31-066

Study Site, Krakow

01-138

Study Site, Warsaw

011026

Study Site, Bucharest

Unknown

Study Site, Barnaul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY